Cognition Therapeutics Completes FDA End-of-Phase 2 Meeting For Zervimesine In Alzheimer’s

Cognition Therapeutics Inc CGTX:

• COGNITION THERAPEUTICS COMPLETES END-OF-PHASE 2 MEETING WITH FDA FOR ZERVIMESINE (CT1812) IN ALZHEIMER’S DISEASE

• COGNITION THERAPEUTICS INC - DISCUSSED PHASE 2 RESULTS AND PHASE 3 PLAN WITH FDA